There will be a final report that is thematically organized and describes key findings and strategic recommendations for Region VIII OASH/OHW to consider supporting future evidence-based program development and implementation, policy recommendations, and future research. Likely Respondents: Data for this assessment will be collected through three mechanisms—a survey of women living in the assessment geography, focus groups with a cross-section of women and other key groups living in the assessment geography, key leaders and stakeholders across a variety of governmental and non-governmental sectors.

The total annual burden hours estimated for this ICR are summarized in the table below.

### Total Estimated Annualized Burden—Hours

<table>
<thead>
<tr>
<th>Form name</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per response (in hours)</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community Survey</td>
<td>500</td>
<td>1</td>
<td>15/60</td>
<td>125</td>
</tr>
<tr>
<td>Focus Groups</td>
<td>240</td>
<td>1</td>
<td>90/60</td>
<td>360</td>
</tr>
<tr>
<td>Interviews</td>
<td>40</td>
<td>1</td>
<td>60/60</td>
<td>40</td>
</tr>
<tr>
<td>Total</td>
<td>780</td>
<td>1</td>
<td>40.4/60</td>
<td>525</td>
</tr>
</tbody>
</table>

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID Peer Review Meeting.

*Date:* September 20–21, 2017.

*Time:* 12:00 p.m. to 4:00 p.m.

*Place:* To review and evaluate contract proposals.

*Contact Person:* Kelly Y. Poe, Ph.D., Scientific: Review Program, Division of Extramural Activities, Room 3F40B, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–9336, poekyb@mail.nih.gov.

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

*AGENCY:* National Institutes of Health, HHS.

*ACTION:* Notice.

*SUMMARY:* The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

*FOR FURTHER INFORMATION CONTACT:* Chris Kornak, 240–627–3705, Chris.Kornak@nih.gov. Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

**SUPPLEMENTARY INFORMATION:**

**Technology description follows.**

**HIV Targets CD62L on Central Memory T Cells Through Viral Envelope Glycans for Adhesion and Induces Selectin Shedding for Viral Release**

**Description of Technology**

Despite the success of anti-retroviral therapy in controlling HIV in infected individuals, treatment is less effective at eliminating HIV viral reservoirs. The nature of HIV reservoirs and the factors controlling their size and release are a major research focus for achieving a cure for HIV/AIDS.

NIAID researchers have identified L-selectin/CD62L as a new target for treating HIV by inhibiting viral release from infected cells. They found that shedding of CD62L on T cells is required for the efficient release of HIV virus from infected cells. Further, they have shown that inhibition of CD62L shedding dramatically reduced HIV–1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L shedding can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

**Potential Commercial Applications**

- New target for HIV therapeutic development.